Adding Olanzapine to Risperidone Eases Schizophrenia Symptoms but Takes a Heavy Metabolic Toll

For decades, psychiatrists facing a patient whose schizophrenia symptoms refuse to yield to a single antipsychotic have reached for a second drug, hoping that two mechanisms will succeed where one has stalled. The practice, known as antipsychotic polypharmacy, is widespread in clinical settings around the world, yet rigorous head-to-head evidence weighing its symptomatic benefits against its physical costs has been remarkably scarce. A new retrospective cohort study from Hangzhou, China, published in BMC Psychiatry, offers one of the most detailed accounting exercises to date, and its verdict is sobering: adding olanzapine to risperidone did sharpen symptom control over eight weeks, but it exacted a steep and consistent metabolic price that clinicians cannot afford to ignore.

The study’s design deserves careful attention because it shapes how much confidence the findings can carry. The researchers drew on the records of 131 hospitalised adults with schizophrenia, each diagnosis confirmed by an independent re-review of the case record against the DSM-5 criteria rather than taken at face value from the chart. Sixty-seven patients received risperidone plus olanzapine, while 64 received risperidone alone, and 124 of the 131 had complete week-eight data available for analysis. Because treatment assignment was not randomised, the two groups could differ in ways that both influenced the choice of combination therapy and shaped the outcomes, a limitation the authors themselves flag prominently.

One of the most consequential imbalances was not in baseline characteristics, which were well matched, including treatment history, but in the total amount of antipsychotic drug each group actually received. When total exposure was converted into olanzapine-equivalent daily doses, the combination group received 77 percent more antipsychotic overall, 30.71 milligrams per day versus 17.35 milligrams per day in the monotherapy arm. Using a common pharmacological model that assumes a maximal effect at full receptor blockade, this translates into hypothetical striatal dopamine D2 receptor occupancy of 87.3 percent for the combination group versus 83.0 percent for monotherapy. This matters because D2 occupancy is thought to be a central driver of antipsychotic efficacy, and it means the apparent symptomatic advantage of the combination cannot be cleanly separated from the simple fact that patients in that arm were receiving more total drug.

The symptomatic results were measured with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms, two instruments that have long served as standard tools for quantifying the distinct dimensions of schizophrenia psychopathology. Positive symptoms encompass hallucinations, delusions, and disorganised thinking, while negative symptoms include blunted affect, social withdrawal, apathy, and poverty of speech, which are often harder to treat and contribute heavily to functional disability. Over the eight weeks, the combination group showed a mean reduction of 33.35 points on the SAPS compared with 24.16 points for monotherapy, a difference of 9.19 points with a 95 percent confidence interval of 13.18 to 5.20. On the SANS, the corresponding reductions were 27.11 versus 18.33 points, a difference of 8.78 points with a confidence interval of 12.48 to 5.08. Both differences were statistically significant after adjustment for multiple comparisons using the Hochberg procedure.

Response rates told a similar story in more clinically interpretable terms. For positive symptoms, 57.1 percent of the combination group met the response threshold compared with 32.8 percent of the monotherapy group. For negative symptoms the gap was wider still, with 46.0 percent versus 13.1 percent achieving response. The negative-symptom finding is particularly striking because negative symptoms have historically been resistant to most pharmacological interventions, and any signal in this domain attracts attention. However, the same confounding by total antipsychotic exposure applies here as well, and it remains possible that simply pushing total D2 blockade higher, whether with one drug or two, would produce a comparable effect.

The metabolic toll was the study’s other co-primary concern, and here the picture was unambiguous. All eight metabolic parameters examined, spanning anthropometric, glycaemic, and lipid measures, deteriorated more in the combination group, with every comparison reaching statistical significance at the adjusted threshold of 0.004 or lower. Weight gain was the most visible manifestation, averaging 3.58 kilograms in the combination arm versus 1.42 kilograms with monotherapy, a difference of 2.16 kilograms over just eight weeks. Clinically meaningful weight gain, defined as an increase of at least 7 percent of body weight, occurred in 39.7 percent of the combination group versus 9.8 percent of the monotherapy group, yielding a number needed to harm of just 3. In practical terms, for every three patients treated with the combination rather than monotherapy, one additional patient would be expected to gain a clinically significant amount of weight within two months.

Olanzapine is well known among the second-generation antipsychotics for its particularly strong association with weight gain and metabolic disturbance, an effect attributed to a combination of histamine H1 receptor antagonism, serotonin 5-HT2C antagonism, and direct effects on appetite regulation and glucose metabolism. Risperidone carries a comparatively lower metabolic burden, which makes the choice to add olanzapine to it a decision that inherently stacks a high-risk agent on top of a lower-risk one. The eight-week window of this study, while sufficient to capture the steepest phase of antipsychotic-associated weight gain, likely understates the longer-term metabolic trajectory, since weight gain and dyslipidaemia tend to continue accumulating well beyond the first two months of exposure.

An important secondary observation was that weight gain was unrelated to symptom improvement within either treatment group. This dissociation is noteworthy because it argues against the possibility that patients who improved more simply ate more or moved less as a byproduct of feeling better, and it also suggests that the metabolic and symptomatic effects of the combination operate through partly independent mechanisms. The exploratory cognitive measure, the Montreal Cognitive Assessment, showed no difference between groups, though the authors caution that this brief screening instrument, readministered in identical form at each visit, has limited sensitivity to change and was not designed as a primary endpoint.

The authors are careful about what their data can and cannot support. Because the comparison was between a two-drug regimen and a one-drug regimen without randomisation, and because the combination group received substantially more total antipsychotic, they conclude that the study does not establish an advantage of combining two agents over adequate dosing of a single one. This distinction is more than semantic. If the benefit of the combination is attributable simply to higher total D2 occupancy, then the same symptomatic gains might be achievable with careful dose optimisation of risperidone alone, potentially sparing patients the metabolic consequences of adding olanzapine. Conversely, if olanzapine’s distinct receptor profile contributes something that risperidone dose escalation cannot, that would be a genuine pharmacological argument for the combination, but the current design cannot distinguish between these possibilities.

The study was conducted at a single centre, the Third People’s Hospital of Fuyang District in Hangzhou, Zhejiang Province, and the retrospective design means that the decision to add olanzapine was made by treating clinicians based on their judgement of insufficient response, introducing the possibility of confounding by indication. Patients selected for combination therapy may have been, on average, more ill or more treatment-resistant at the point of escalation, though the balance in baseline characteristics and treatment history suggests this concern was at least partially addressed. The ethics committee waived written informed consent because the study involved only retrospective analysis of de-identified, routinely collected clinical data with no patient contact, and all data were anonymised before analysis.

For clinicians, the practical message is one of caution rather than prohibition. The combination of risperidone and olanzapine did produce larger symptomatic improvements across both positive and negative symptom domains in this cohort, and the effect sizes were not trivial. But the metabolic penalty was equally consistent, affecting every parameter measured, and the magnitude of weight gain observed in nearly 40 percent of combination-treated patients within eight weeks is a signal that demands active monitoring of weight, glucose, and lipids whenever this strategy is employed. The finding that total antipsychotic exposure differed so substantially between groups also serves as a reminder that in real-world prescribing, the question is rarely simply whether to combine drugs but how much total pharmacological burden a patient is being asked to carry, and whether that burden could be achieved more safely with a single well-titrated agent.

Subject of Research: Symptomatic benefit and metabolic cost of combining olanzapine with risperidone in schizophrenia

Article Title: Symptomatic benefit and metabolic cost of adding olanzapine to risperidone in schizophrenia: an 8-week retrospective cohort study

Article References: Shen, L., Han, X., Shen, J., Shen, F., Li, Y., & Li, H. (2026). Symptomatic benefit and metabolic cost of adding olanzapine to risperidone in schizophrenia: an 8-week retrospective cohort study. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08766-8

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08766-8

Keywords: schizophrenia, antipsychotic polypharmacy, olanzapine, risperidone, metabolic side effects, weight gain, negative symptoms, D2 receptor occupancy, psychopharmacology, retrospective cohort study, Symptomatic, benefit